Risk factors for adverse events in first-line Helicobacter pylori eradication therapy with vonoprazan, amoxicillin, and clarithromycin

Vonoprazan is an oral potassium-competitive acid blocker that has a greater acid-inhibitory effect than proton pump inhibitors (PPIs). Many studies have shown that vonoprazan-based triple therapy had greater efficacy than PPI-based triple therapy for Helicobacter pylori eradication [ [1] Sugimoto M. Yamaoka Y. Role of vonoprazan in Helicobacter pylori eradication therapy in Japan. Front Pharmacol. 2019; 9: 1560 Crossref PubMed Scopus (40) Google Scholar ]. However, limited information is available on the risk factors for adverse events (AEs) in vonoprazan-besed triple therapy.